Newsroom | 98755 results

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma announces key results of Phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab...

LAS VEGAS & PANAMA CITY, Panama--(BUSINESS WIRE)--Auragens today announced it has been named Stem Cell Treatment Center of the Year 2026 by Life Sciences Review, becoming the first organization to receive the publication's highest distinction for two consecutive years. While the award recognizes excellence in patient care, it also reflects a broader transformation taking place within regenerative medicine—one in which scientific rigor, manufacturing quality, regulatory oversight, and integrated...

WILLIAMSON, W.Va.--(BUSINESS WIRE)--Halo340B today called on Federally Qualified Health Centers and other 340B covered entities to take a more strategic and mission-driven approach to understanding their 340B gross-to-net performance. For covered entities, gross-to-net should be viewed as the difference between the total 340B opportunity available to the organization and the net value actually retained for reinvestment into patient care. That net value can be affected by missed eligible claims,...

WASHINGTON--(BUSINESS WIRE)--AMERICAN WOMEN ARE BEING LET DOWN: ONLY 1-IN-3 VOTERS SAY THE U.S. HEALTH CARE SYSTEM IS MEETING WOMEN’S NEEDS...

LA JOLLA, Calif.--(BUSINESS WIRE)--Arialys Announces U.S. FDA Fast Track Designation for ART5803, the First Precision Therapeutic Candidate in Development for the Treatment of ANRE...

TEL AVIV, Israel & ZUG, Switzerland--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven bios...

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its CEO, Rob Fried, will participate in a virtual fireside chat hosted by KCSA Strategic Communications on Wednesday, July 15, 2026, at 8 am PDT. During the discussion, Mr. Fried will discuss the recently launched pharmaceutical program for rare genetic diseases and aging-related disorders, the C...

SAN DIEGO--(BUSINESS WIRE)--ClearNote Health announced Kevin Keegan, currently president and chief operating officer, has been appointed CEO, effective July 31, 2026....

BENTONVILLE, Ark. & NEW YORK--(BUSINESS WIRE)--Sam’s Club and WW International, Inc. (“Weight Watchers”), two trusted brands that both champion membership and community, today announced a new collaboration to create a more connected, affordable wellness experience. The joint initiative between Sam’s Club, a leading membership retail club, and Weight Watchers, a legacy leader in science-backed weight health, combines expert guidance and nutrition counseling with access to affordable healthy food...

BETHESDA, Md. & NEW YORK--(BUSINESS WIRE)--Forus, the leader in AI-powered medication access and prior authorization, and the American Gastroenterological Association (AGA), the nonprofit medical society dedicated to advancing the science and practice of gastroenterology, today announced a strategic partnership to improve how the more than 60 million Americans living with digestive diseases get the therapies their clinicians prescribe. Forus is the AI-powered network that automates the path fro...